Rivaroxaban

Generic Name
Rivaroxaban
Brand Names
Xarelto, Rivaroxaban Accord, Rivaroxaban Viatris (previously Rivaroxaban Mylan)
Drug Type
Small Molecule
Chemical Formula
C19H18ClN3O5S
CAS Number
366789-02-8
Unique Ingredient Identifier
9NDF7JZ4M3
Background

Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, ...

Indication

Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurre...

Associated Conditions
Cardiovascular Mortality, Deep Vein Thrombosis, Deep vein thrombosis recurrent, Major Adverse Cardiovascular Events, Myocardial Infarction, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Recurrent Venous Thromboembolism, Stroke, Systemic Embolism, Thrombosis, Venous Thromboembolism
Associated Therapies
-
Clinical Trials
Related News

Evaluation of WATCHMAN Left Atrial Appendage Occlusion Device in Patients With Atrial Fibrillation Versus Rivaroxaban

First Posted Date
2015-09-15
Last Posted Date
2015-09-24
Lead Sponsor
Shulin Wu
Target Recruit Count
200
Registration Number
NCT02549963
Locations
🇨🇳

The second Affiliated Hospital of Guangzhou medical University, Guangzhou, Guangdong, China

🇨🇳

Nanfang Hospital, Guangzhou, Guangdong, China

🇨🇳

Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangzhou, Guangdong, China

and more 6 locations

XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis

First Posted Date
2015-07-23
Last Posted Date
2018-09-27
Lead Sponsor
Susan Smyth
Target Recruit Count
10
Registration Number
NCT02506985

Rivaroxaban for Scheduled Work-up of DVT - The Ri-Schedule Study

Phase 3
Completed
Conditions
Deep Venous Thrombosis
Interventions
Drug: Rivaroxaban
First Posted Date
2015-07-01
Last Posted Date
2019-01-23
Lead Sponsor
Ostfold Hospital Trust
Target Recruit Count
625
Registration Number
NCT02486445
Locations
🇳🇴

Ostfold Hospital Trust, Fredrikstad, Ostfold, Norway

PROphylaxis in NOn Major Orthopaedic Surgery

First Posted Date
2015-03-30
Last Posted Date
2018-12-07
Lead Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Target Recruit Count
3608
Registration Number
NCT02401594
Locations
🇫🇷

CHU AMIENS Picardie, Amiens, France

🇫🇷

CHU Angers, Angers, France

🇫🇷

Clinique Générale d'ANNECY, Annecy, France

and more 35 locations

Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF

Phase 3
Terminated
Conditions
ATRIAL FIBRILLATION
Interventions
Other: standard of care
Drug: Rivaroxaban
First Posted Date
2015-03-12
Last Posted Date
2024-06-06
Lead Sponsor
Montreal Heart Institute
Target Recruit Count
1238
Registration Number
NCT02387229
Locations
🇨🇦

Cardio 1, Winnipeg, Manitoba, Canada

🇨🇦

St. Boniface Hospital, Winnipeg, Manitoba, Canada

🇨🇦

CIUSSS du Saguenay-Lac-Saint-Jean, Chicoutimi, Quebec, Canada

and more 36 locations

Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty

First Posted Date
2015-03-05
Last Posted Date
2015-03-05
Lead Sponsor
Samsung Medical Center
Target Recruit Count
639
Registration Number
NCT02379663

Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium

Phase 4
Completed
Conditions
Atherosclerosis
Interventions
Drug: Warfarin
Drug: rivaroxaban
First Posted Date
2015-03-03
Last Posted Date
2024-10-14
Lead Sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Target Recruit Count
110
Registration Number
NCT02376010
Locations
🇺🇸

Los Angeles Biomedical Research Institute, Torrance, California, United States

Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran

First Posted Date
2015-01-06
Last Posted Date
2015-08-06
Lead Sponsor
Yokohama City University Medical Center
Target Recruit Count
200
Registration Number
NCT02331602
Locations
🇯🇵

Omori Red Cross Hospital, Ohta, Tokyo, Japan

🇯🇵

International Goodwill Hospital, Yokohama, Kanagawa, Japan

🇯🇵

Yokohama City University Hospital, Yokohama, Kanagawa, Japan

and more 13 locations

RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial

Phase 2
Completed
Conditions
Valvular Heart Disease
Interventions
Drug: Rivaroxaban
Drug: Warfarin
First Posted Date
2014-12-01
Last Posted Date
2022-04-12
Lead Sponsor
Hospital do Coracao
Target Recruit Count
1005
Registration Number
NCT02303795
Locations
🇧🇷

Associação do Sanatório Sírio - Hospital do Coração HCor, São Paulo, SP, Brazil

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

First Posted Date
2014-11-18
Last Posted Date
2017-12-26
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
3037
Registration Number
NCT02293395
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy